[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Rhythm Pharmaceuticals Inc (RYTM)

Rhythm Pharmaceuticals Inc (RYTM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,914,190
  • Shares Outstanding, K 68,533
  • Annual Sales, $ 189,760 K
  • Annual Income, $ -196,540 K
  • EBIT $ -197 M
  • EBITDA $ -196 M
  • 60-Month Beta 1.88
  • Price/Sales 41.33
  • Price/Cash Flow N/A
  • Price/Book 63.80

Options Overview Details

View History
  • Implied Volatility 64.03% (+7.35%)
  • Historical Volatility 43.41%
  • IV Percentile 57%
  • IV Rank 37.23%
  • IV High 106.20% on 12/02/25
  • IV Low 39.01% on 08/11/25
  • Expected Move (DTE 7) 3.38 (3.12%)
  • Put/Call Vol Ratio 1.33
  • Today's Volume 14
  • Volume Avg (30-Day) 117
  • Put/Call OI Ratio 0.48
  • Today's Open Interest 3,320
  • Open Int (30-Day) 3,683
  • Expected Range 105.02 to 111.78

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.82
  • Number of Estimates 5
  • High Estimate $-0.80
  • Low Estimate $-0.84
  • Prior Year $-0.75
  • Growth Rate Est. (year over year) -9.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
84.90 +27.68%
on 06/11/26
115.92 -6.49%
on 07/09/26
+22.69 (+26.47%)
since 06/10/26
3-Month
79.40 +36.52%
on 05/01/26
115.92 -6.49%
on 07/09/26
+24.01 (+28.45%)
since 04/10/26
52-Week
74.50 +45.50%
on 03/30/26
122.20 -11.29%
on 12/11/25
+19.36 (+21.74%)
since 07/10/25

Most Recent Stories

More News
Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity

BOSTON, July 08, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare...

RYTM : 108.40 (-6.13%)
Intel Stock and 3 Other Winners I Found Using Barchart’s High-Octane Stock Screener

One feature within the Barchart Stock Screener tool that resonated with me is a pre-built filter known as the J-Pattern or J-Curve.

INTC : 109.84 (-2.40%)
RYTM : 108.40 (-6.13%)
$SPX : 7,575.39 (+0.42%)
GEV : 1,091.57 (+1.52%)
MRNA : 68.27 (-10.83%)
Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026

 -- Setmelanotide therapy achieved robust, sustained and clinically significant weight loss in patients with acquired HO at 2.5 years -- - - Bivamelagon therapy achieved progressive reductions...

RYTM : 108.40 (-6.13%)
 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026

 -- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in...

RYTM : 108.40 (-6.13%)
Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome

BOSTON, June 12, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare...

RYTM : 108.40 (-6.13%)
Rhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026

BOSTON, May 29, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare...

RYTM : 108.40 (-6.13%)
3 Gold-Medal Mutual Funds to Buy Now

These mutual funds are the crème de la crème of their respective investment categories.

NVDA : 210.96 (+4.03%)
GOOGL : 357.18 (-0.48%)
ONC : 298.70 (-1.36%)
TDVG : 49.52 (+0.26%)
RYTM : 108.40 (-6.13%)
MU : 979.30 (-1.24%)
DODIX : 12.60 (-0.08%)
V : 348.97 (+0.22%)
ROST : 222.88 (+1.03%)
PRDGX : 89.79 (+0.29%)
CB : 347.83 (+0.01%)
WMT : 113.90 (+1.51%)
Rhythm Pharmaceuticals Announces Publication of New Bardet-Biedl Syndrome Diagnostic Algorithm in the American Journal of Medical Genetics

BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare...

RYTM : 108.40 (-6.13%)
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

BOSTON, May 26, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare...

RYTM : 108.40 (-6.13%)
Rhythm Pharmaceuticals Announces New Data Presentations at the 2026 European Congress of Endocrinology

– Real world data showed clinically meaningful BMI reductions with setmelanotide in 62 adults with 12-month data living with acquired hypothalamic obesity (HO) in France – – Phase 3 analyses...

RYTM : 108.40 (-6.13%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Relative Strength just crossed below 70%. The market has dropped from overbought territory. Beware of a potential mean reversion.

See More Share

Business Summary

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. It focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies which result in life-threatening metabolic disorders. The Company's product candidate principally consists of setmelanotide,...

See More

Key Turning Points

3rd Resistance Point 119.56
2nd Resistance Point 117.25
1st Resistance Point 112.83
Last Price 108.40
1st Support Level 106.10
2nd Support Level 103.79
3rd Support Level 99.37

See More

52-Week High 122.20
Last Price 108.40
Fibonacci 61.8% 103.98
Fibonacci 50% 98.35
Fibonacci 38.2% 92.72
52-Week Low 74.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.